Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2009
11/10/2009US7615616 Detecting cell wall anchored surface proteins and developing vaccines to diagnose, prevent and treat enterococcus, streptococcus, staphylococcus and bacillus infections
11/10/2009US7615615 Modified interferon beta with reduced immunogenicity
11/10/2009US7615564 Such as N5-[1-(2-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine; Rho kinase inhibitors; hypertension, asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, vision disorders, autoimmune diseases, chronic renal failure
11/10/2009US7615553 E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation
11/10/2009US7615548 Method to inhibit ischemia and reperfusion injury
11/10/2009US7615543 Complexes with C-reactive protein (CRP) molecules; rheumatoid arthritis, juvenile chronic (rheumatoid) arthritis, ankylosing spondylitis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Reiter's disease, Crohn's disease and familial Mediterranean fever
11/10/2009US7615229 useful in inducing a protective immune response against NTHi in an immunized human
11/10/2009US7615228 Chimeric protein containing specific polypeptide and a conserved fragment of hemagglutin antigen from influenza virus
11/10/2009US7615207 Methods for treating irritable bowel syndrome
11/10/2009CA2519348C Composition comprising zinc-containing layered material with a high relative zinc lability
11/10/2009CA2481482C Tropane derivatives as ccr5 modulators
11/10/2009CA2476257C O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
11/10/2009CA2459930C Method of treating middle ear infections
11/10/2009CA2417401C Benzofuran derivatives and their use as antibacterial agents
11/10/2009CA2411572C 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
11/10/2009CA2397614C Honey based wound dressing
11/10/2009CA2378792C Aminothiazole derivatives and their use as crf receptor ligands
11/10/2009CA2335903C Novel cyclosporin with improved activity profile
11/10/2009CA2315262C Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
11/10/2009CA2251027C Defective viral vaccine particles obtained in vivo or ex vivo
11/10/2009CA2197659C Antibacterial composition containing multimeric alpha-lactalbumin
11/05/2009WO2009135199A2 Vaccine compositions and methods
11/05/2009WO2009134856A2 Pharmaceutical gallium compositions and methods
11/05/2009WO2009134769A1 Nanoparticles for use in pharmaceutical compositions
11/05/2009WO2009134738A1 Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
11/05/2009WO2009134637A1 Piperazine-based ccr5 antagonist tablet dosage form
11/05/2009WO2009134616A2 Novel inhibitors of hepatitis c virus replication
11/05/2009WO2009134347A2 Sulfoalkyl ether cyclodextrin compositions
11/05/2009WO2009134203A1 New peptidomimetic compounds
11/05/2009WO2009134112A1 Pharmaceutical formulation that comprises a bleached extract of ageratina pichinchensis for treating onychomycosis
11/05/2009WO2009133882A1 Bacterial toxin vaccine
11/05/2009WO2009133863A1 Immunopotentiating agent comprising ep1 agonist
11/05/2009WO2009133560A1 Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
11/05/2009WO2009133442A1 Azabicyclic compounds, preparation thereof and use of same as drugs, especially beta-lactamase inhibitors
11/05/2009WO2009133379A2 Antifungal target
11/05/2009WO2009133278A1 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest
11/05/2009WO2009133249A1 Peptide vaccine for influenza virus
11/05/2009WO2009133073A1 Propolis extract
11/05/2009WO2009111218A3 Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
11/05/2009WO2009109869A3 Alcohol antimicrobial skin sanitizing compositions including cationic compatible thickeners
11/05/2009WO2009105192A3 Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
11/05/2009WO2009104147A3 Azatricyclic antibiotic compounds
11/05/2009WO2009102497A3 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
11/05/2009WO2009077844A3 Inhibitors of biofilm formation of gram-positive and gram-negative bacteria
11/05/2009WO2009071480A3 Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
11/05/2009WO2009046879A3 Use of the combination of npy and nociceptin as a therapeutic agent
11/05/2009WO2009043526A3 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent
11/05/2009WO2009040051A9 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent
11/05/2009WO2009040005A9 Use of the peptide rfmwmr as a therapeutic agent
11/05/2009WO2009033819A3 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
11/05/2009WO2009033797A3 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
11/05/2009WO2009033785A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
11/05/2009WO2009033784A3 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
11/05/2009WO2009033738A3 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
11/05/2009WO2009033712A3 Use of melanotan ii as a therapeutic agent
11/05/2009WO2008147427A3 Antiviral colloidal silver composition
11/05/2009WO2008130261A9 Treatment of infections by carbon monoxide
11/05/2009US20090275667 Use of allicin as preservative, as disinfectant, as antimicrobial or as biocidal agent
11/05/2009US20090275644 Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof
11/05/2009US20090275594 3-hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents
11/05/2009US20090275583 Antiviral compounds and use thereof
11/05/2009US20090275577 Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
11/05/2009US20090275572 Fab i inhibitors
11/05/2009US20090275560 Organic compounds
11/05/2009US20090275548 Compounds and methods for activated therapy
11/05/2009US20090275536 Antibacterial Agents
11/05/2009US20090275535 Antiviral phosphonate analogs
11/05/2009US20090275508 Use of thymosin alpha 1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection
11/05/2009US20090275507 Contraceptive composition
11/05/2009US20090275499 Nonstructural protein ns1 as a novel therapeutic target against flaviviruses
11/05/2009US20090274754 Dual action, inhaled formulations providing both an immediate and sustained release profile
11/05/2009US20090274727 Recombinant RSV Virus Expression Systems And Vaccines
11/05/2009US20090274725 Materials and Methods for Detecting, Preventing, and Treating Retroviral Infection
11/05/2009US20090274724 Novel recombinant and mutant adenoviruses
11/05/2009US20090274718 Chimeric proteins that induce effects directed against viruses
11/05/2009US20090274717 Genes and proteins, and their use
11/05/2009US20090274708 Recombinant Toxin Fragments
11/05/2009US20090274699 Ul16 binding protein 4
11/05/2009US20090274686 Nucleoside phosphonate derivatives
11/05/2009US20090274680 Human Phospholipases
11/05/2009US20090274670 Dph2 gene deletion mutant and uses thereof
11/05/2009US20090274669 Dendritic Cells Transiently Transfected with a Membrane Homing Polypeptide and their use
11/05/2009US20090274657 Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
11/05/2009US20090274656 Hepatitis c virus inhibitors
11/05/2009US20090274655 2-carboxy thiophene derivatives as anti viral agents
11/05/2009US20090274653 Interleukin-2 mutants with reduced toxicity
11/05/2009US20090274652 Hepatitis C Virus Inhibitors
11/05/2009US20090274651 Therapeutic agent for infections, and treatment method using the same
11/05/2009US20090274650 Inhibitors of aspartyl protease
11/05/2009US20090274649 Bispecific Antibody Point Mutations for Enhancing Rate of Clearance
11/05/2009US20090274648 Hepatitis c virus inhibitors
11/05/2009US20090274635 Bactericide having selectivity to cariogenic bacterium, and a method for sterilization of cariogenic bacterium
11/05/2009DE102009015608A1 Verwendung von Alkylglycosiden oder Alkylglycosidmischungen als Wirkstoffe zur Hemmung des mikrobiellen Wachstums und Zusammensetzungen, welche die genannten Alkylglycoside enthalten The use of alkyl glycosides or Alkylglycosidmischungen as active ingredients for the inhibition of microbial growth, and compositions which contain said alkylglycosides
11/05/2009DE102008021756A1 Propolis-Extrakt Propolis Extract
11/05/2009CA2726007A1 Vaccine compositions and methods
11/05/2009CA2723020A1 Azabicyclic compounds, preparation thereof and use of same as drugs, especially beta-lactamase inhibitors
11/05/2009CA2722938A1 New peptidomimetic compounds
11/05/2009CA2722765A1 Nanoparticles for use in pharmaceutical compositions
11/05/2009CA2722571A1 Pharmaceutical gallium compositions and methods
11/05/2009CA2721959A1 Antifungal target
1 ... 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 ... 1798